Articles by Dr. Julie Brahmer, MD
- Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC
- Brahmer Highlights Next Steps for Osimertinib in EGFR-Mutant NSCLC
- Brahmer Highlights Practice-Changing Data in HER2-Mutated NSCLC
- Brahmer Shares Next Steps for Immunotherapy in Metastatic NSCLC
- Five-Year Survival Rate an Impressive 16% With Nivolumab in Advanced NSCLC